medigraphic.com

2003, Número s1

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2003; 41 (s1)


Guía clínica para el diagnóstico y tratamiento de la diabetes mellitus tipo 2

Oviedo MMA, Espinosa LF, Reyes MH, Trejo y PJA, Gil VE

Idioma: Español
Referencias bibliográficas: 52
Paginas: 27-46
Archivo PDF: 587.78 Kb.


RESUMEN

Dada su complejidad, la dificultad de su control y las complicaciones que se producen cuando este control no se logra, la diabetes mellitus tipo 2 es un trastorno metabólico que representa una de las principales causas de consulta en atención primaria y un reto para su tratamiento. La hiperglucemia crónica de la diabetes se acompaña en el largo plazo de daño, disfunción e insuficiencia de diversos órganos, en especial ojos, riñones, nervios, corazón y vasos sanguíneos. Esta guía propone acciones para la detección, el diagnóstico, el tratamiento no farmacológico y farmacológico de la diabetes mellitus tipo 2, así como la identificación precoz de las complicaciones de la enfermedad en el primer nivel de atención. Para la elaboración de la guía se seleccionaron las mejores evidencias de las bases de datos Cochrane Library y Medline, las guías clínicas publicadas y se siguieron los criterios propuestos por American Diabetes Association, adaptados a los recursos del Instituto Mexicano del Seguro Social. Se consultó el proyecto de modificación de la norma oficial mexicana para la prevención, tratamiento y control de la diabetes. Se enfatiza en las recomendaciones del plan de alimentación y de ejercicio físico como parte fundamental en el tratamiento integral del paciente diabético.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;25:S33-S49.

  2. Secretaría de Salud. Proyecto de modificación a la Norma Oficial Mexicana NOM-015-SSA2-1994 para la prevención, tratamiento y control de la diabetes. Rev Med IMSS 2000;38(6):477-495.

  3. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR; Ann Pharmacother, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998;21:518-524.

  4. Engelgau ME, Narayan KMV, Herman WH. Screeening for type 2 diabetes. (Technical review). Diabetes Care 2000;10:1563-1580.

  5. Engelgau MM, Thompson TJ, Smith PJ, Herman WH, Aubert RE, Gunter EW, Wetterhall SF, Sous ES, Ali MA. Screening for diabetes mellitus in adults: the utility of random capillary blood glucose measurements. Diabetes Care 1995;18:463-466.

  6. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2000;23(Suppl):S20-S23.

  7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344:1343-1350.

  8. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The DaQing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.

  9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.

  10. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.

  11. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.

  12. Evans JMM, Newton RW, Ruta DA, MacDonald TM, Stevenson RJ, Morris AD. Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes data-base. BMJ 1999;319:83-86.

  13. Matsuoka K. A diabetes care team-role of diabetes specialists and certified diabetes educator. Jpn J Clin Pathol 2001;49(12):1212-1217.

  14. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002;25:148-198.

  15. American Diabetes Association. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. (Position statement). Diabetes Care 2002;25(Suppl):S50-S60.

  16. Barnard RJ, Jung T, Inkeles SB. Diet and exercise in the treatment of NIDDM. Diabetes Care 1994;17 (12):1469-1472.

  17. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzmmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. JCE & M 1993;77(5):1287-1293.

  18. Oviedo MA, Pérez-Cuevas R, Catañeda R, Reyes H. Guía de alimentación para el paciente diabético tipo 2. Una propuesta aplicable en atención primaria. Rev Med IMSS 2000;38(4):285-293.

  19. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care 2002;25(Suppl 1):S64-S68.

  20. Centers for Disease Control and Prevention and the American College of Sports Medicine. Physical activity and public health: a recommendation. JAMA 1995;273:402-407.

  21. American College of Sprots Medicine. The recommendend quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness in healthy adults. (Position statement). Med Sci Sports Exerc 1990;20:265-274.

  22. American Diabetes Association. Diabetes and exercise: the risk-benefit profile. En: Devlin JT, Ruderman N, editors. The health professional’s guide to diabetes and exercise. Alexandria, VA: American Diabetes Association; 1995. p. 3-4.

  23. García V. Ejercicio y diabetes en diabetes mellitus. Segunda edición. México: McGraw-Hill-Interamericana; 1999. p. 315-327.

  24. De-Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. (Review). Ann Inter Med 1999; 131(4):281-303.

  25. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989; 1:1356-1359.

  26. De-Fronzzo RA. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-687.

  27. Blaum CS, Vélez L, Hiss RG, Halter JB. Characteristics related too poor glycemic control in NIDDM patients in community practice. Diabetes Care 1997;20:7-11.

  28. Rapties SA, Hatziagelaki E, Dimitriadis G, Draeger KE, Pfeiffer C, Raptis AE. Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man. Exp Clin Endocrinol Diabetes 1999;107:350-355.

  29. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998;32:1044-1052.

  30. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-754.

  31. De-Fronzo RA, Barzilai N, Simonson DC. Mechanism of metformin actino in obese and lean noninsulindependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-1301.

  32. Cusi K, De-Fronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89-131.

  33. 33 Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995;11 (Suppl):S57-S62.

  34. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, Andre P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upperbody fat distribution. Diabetes Care 1996; 19:920-926.

  35. Wilhom BE, Myrhed M. Metformin-associated lactic acidosis in Sweden 1977-1991. Eur J Clin Pharmacol 1993;44:589-591.

  36. Misbin RI, Green L, Stadel BV, Guerguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients treated with metformin. N Engl J Med 1998;338: 265-266.

  37. Reaven GM, Johnston P, Hollenbeck CB, Skowronski R, Zhang JC, Goldfine ID, et al. Combined metforminsulfonylurea treatment of patients with noninsulindependent diabetes in fair to poor glycemic control. J Clin Endocrinol Metab 1992;74:1020-1026.

  38. Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994;121:928-935.

  39. Coniff RF, Shapiro JA, Robbins D, Kleinfield R, Seaton TB, Beisswenger P, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose comparison study. Diabetes Care 1995;18:817-824.

  40. Campbell LK, White JR, Campbell RK. Acorbose: its role in the treatment of diabetes mellitus. Ann Pharmacother 1996;30:1255-1262

  41. Lebovitz HE. A new oral therapy for diabetes management: alpha-glucosidase inhibition with acarbose. Clin Diabetes 1995;13:99-103.

  42. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-309.

  43. The DCCT Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 1995;47: 1703-1720.

  44. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998;317:703-713.

  45. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.

  46. Laffel LMB, McGill JB, Gans DJ, and the North American Microalbuminuria Study Group (NAMSG). The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995; 99:497-504.

  47. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 1998;128:982-988.

  48. Ravid M, Lang R, Rachmani R, Lishner M. Longterm renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 1996;156:286-289.

  49. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE Study and Micro-HOPE Study. Lancet 2000;355:253-259.

  50. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157:2413-2446.

  51. 51 Hansson L, Zanchett A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive bloodpressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755-1762.

  52. 52 Cheng A, Braunstein J, Dennison Ch, Nass C, Blumenthal RS. Reducing global risk for cardiovascular disease: using lyfestyle changes and pharmacotherapy. Clin Cardiol 2002;25:205-212.




2020     |     www.medigraphic.com